Roy S. Herbst, MD, PhD

Articles

EGFR mNSCLC: Future Directions

March 20th 2025

Panelists discuss how despite significant advances in EGFR-targeted therapy, critical unmet needs persist in EGFR-positive non–small cell lung cancer (NSCLC), including the need for better strategies to combat resistance mechanisms, more effective treatments for brain metastases, improved options for uncommon EGFR mutations, and the development of biomarker-driven approaches to optimize sequencing of available therapies.

MARIPOSA: Clinical Implications

March 13th 2025

Panelists discuss how the MARIPOSA trial demonstrated strong efficacy with amivantamab plus lazertinib that appears comparable to FLAURA2’s results with osimertinib plus chemotherapy, although cross-trial comparisons should be interpreted cautiously given differences in study populations and the need for mature overall survival data from both trials.

Managing AEs With Osimertinib

March 6th 2025

Panelists discuss how managing adverse events (AEs) with osimertinib requires proactive monitoring and intervention, with monotherapy generally being well-tolerated aside from common AEs like rash and diarrhea.

CNS Activity in EGFR mNSCLC

February 27th 2025

Panelists discuss how FLAURA2's impressive progression-free survival (PFS) benefit with osimertinib plus chemotherapy was particularly pronounced in patients with extrathoracic metastases, suggesting this combination approach may be especially valuable for this higher-risk population, though careful consideration of individual patient factors and toxicity management remains important in treatment selection.

FLAURA and FLAURA2: Key Efficacy and Safety Data

February 20th 2025

Panelists discuss how osimertinib monotherapy demonstrated robust progression-free survival and overall survival benefits in FLAURA, while FLAURA2 showed that adding chemotherapy to osimertinib further improved progression-free survival (PFS) although overall survival (OS) data remains immature, leading to ongoing debate about the optimal first-line approach.

EGFR mNSCLC: Treatment Overview and Challenges

February 13th 2025

Panelists discuss how EGFR tyrosine kinase inhibitors (TKIs) have revolutionized first-line treatment for EGFR-positive non–small cell lung cancer (NSCLC).

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

November 14th 2024

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

Dr Herbst on Notable Research Avenues for Patients With Unmutated NSCLC

October 28th 2024

Roy S. Herbst, MD, PhD, discusses ongoing, planned, and future research for the management of unmutated non–small cell lung cancer.

Dr Herbst on the Evolution of Targeted Therapies for EGFR+ NSCLC

August 2nd 2024

Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.

Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC

July 24th 2024

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.

Dr Herbst on Adjuvant Osimertinib in EGFR-mutant NSCLC

June 4th 2023

Roy S. Herbst, MD, PhD, discusses findings from the overall survival analysis of the phase 3 ADAURA trial of adjuvant osimertinib in patients with stage IB to IIIA resected non–small cell lung cancer harboring EGFR mutations.

Dr Herbst on the Implications of the AEGEAN Trial in NSCLC

April 24th 2023

Roy S. Herbst, MD, PhD, discusses the implications of the phase 3 AEGEAN trial in patients with resectable non–small cell lung cancer.

Dr. Herbst on the FDA Approval of Adjuvant Pembrolizumab in NSCLC

February 2nd 2023

Roy S. Herbst, MD, PhD, discusses the significance of the FDA approval of adjuvant pembrolizumab in patients with non–small cell lung cancer.

Dr. Herbst on the Evolution of Targeted Therapies in NSCLC

April 5th 2022

Roy S. Herbst, MD, PhD, discusses the evolving treatment landscape of targeted therapies in non–small cell lung cancer.

Dr. Herbst on the Approval of Adjuvant Osimertinib in EGFR+ NSCLC

January 6th 2021

Roy S. Herbst, MD, PhD, discusses the approval of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Dr. Herbst on Biomarkers for Immunotherapy Response in NSCLC

December 16th 2020

Roy S. Herbst, MD, PhD, discusses biomarkers for immunotherapy response that are currently under investigation in non–small cell lung cancer (NSCLC).

Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLC

June 2nd 2020

Roy S. Herbst, MD, PhD, discusses the benefit of adjuvant osimertinib demonstrated in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial.

Dr. Herbst on Combination of Nivolumab and Ipilimumab in Patients With NSCLC

January 22nd 2020

Roy S. Herbst, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced non–small-cell lung cancer (NSCLC).

Dr. Herbst on Immuno-Oncology Combinations in Lung Cancer

July 26th 2019

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses combinations with immunotherapy in lung cancer.

Dr. Herbst on Immune Resistance in Lung Cancer

November 12th 2018

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.